Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0UJ0D
|
||||
| Former ID |
DNCL003634
|
||||
| Drug Name |
ISIS-FGFR4Rx
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Phase 2 | [1] | ||
| Company |
ISIS pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | FGF-4 receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | FGF signaling pathway | ||||
| Pathway Interaction Database | FGF signaling pathway | ||||
| Reactome | PI3K Cascade | ||||
| PIP3 activates AKT signaling | |||||
| FGFR4 ligand binding and activation | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Phospholipase C-mediated cascade | |||||
| FRS-mediated FGFR4 signaling | |||||
| SHC-mediated cascade:FGFR4 | |||||
| PI-3K cascade:FGFR4 | |||||
| Negative regulation of FGFR4 signaling | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
| PIP3 activates AKT signaling | |||||
| Signaling by FGFR | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02476019) A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.